During Thursday’s Current trade, Shares of Kimco Realty Corp (NYSE:KIM), lost -0.58% to $24.09.
RioCan Real Estate Investment Trust (“RioCan”) (REI-UN.TO) and Kimco Realty Corp. (“Kimco”) (KIM) declare that after fifteen successful years as partners, RioCan and Kimco have agreed to unwind their Canadian joint venture. The portfolio of 35 jointly owned properties (“RioKim Portfolio”) will be divided into three groups:
- the first group is a collection of 22 properties selected by RioCan that will be attained in two stages: 19 properties during the third quarter of 2015 and three properties in the first quarter of 2016;
- the second group comprises of ten institutional-quality retail assets which the partners have agreed to market for sale, one of which is presently under a conditional contract to be sold; and
- the third group of assets comprises three transitional properties that were formerly occupied by Target, which will be dealt with at a future date.
Kimco Realty Corporation is an independent real estate investment trust. The firm invests in the real estate markets across North America. It is primarily engaged in acquisitions, development, and administration of neighborhood and community shopping centers.
Shares of The Western Union Company (NYSE:WU), declined -1.63% to $18.15, during its current trading session.
Salesforce [ CRM], the Customer Success Platform and world’s #1 CRM company, declared recently that Western Union [ WU] is transforming engagement with customers — and its network of more than 500,000 agents — with Salesforce. Western Union is using the power of Sales Cloud, Community Cloud, Analytics Cloud and App Cloud to automate formerly paper-based processes, which has reduced the time needed to onboard a new agent.
In addition, custom apps built on App Cloud assist Western Union agents comply with complex financial services regulations and provide them with access to the latest company marketing collateral. Commercial customers are able to use custom apps for credit administration and transaction invoices, and business intelligence empowers Western Union to make critical business decisions through access to the vast amount of agent and location data.
The Western Union Company provides money movement and payment services worldwide. The company operates in three segments: Consumer-to-Consumer, Consumer-to-Business, and Business Solutions. The Consumer-to-Consumer segment offers cash money transfer services involving walk-in agent locations.
Valeant Pharmaceuticals Intl Inc NYSE:VRX), during its Thursday’s current trading session decreased -3.58% to $209.47.
Valeant Pharmaceuticals International, Inc.’s (VRX) wholly owned partner, Bausch + Lomb, and Nicox S.A. (NYSE Euronext Paris: COX) recently declared that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for VESNEO(TM) (latanoprostene bunod ophthalmic solution 0.024%), an intraocular pressure (IOP) lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma or ocular hypertension. If approved, VESNEO will be the first nitric oxide donating prostaglandin receptor agonist accessible for the above indication.
Upon instillation in the eye, latanoprostene bunod is rapidly metabolized to two actives; latanoprost acid, a prostaglandin analog, and nitric oxide. Nitric oxide is an important physiological signaling molecule, which plays a key role in IOP regulation in healthy eyes. VESNEO is thought to enhance aqueous humor outflow by acting on both the uveoscleral (non-conventional) pathway via latanoprost acid, and trabecular meshwork and Schlemm’s canal (conventional pathway) via nitric oxide signaling.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
